Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
OwnerAngela Brodie, Vincent Njarinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerAngela Brodie, Vincent Njarinventors
Estimating the term…
Described are steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β-ol or analogs thereof with tributylstannyl diazines. The compounds are potent inhibitors of human CYP17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds are useful for the treatment of human prostate cancer.
A method for treating an androgen dependent prostate disease the method comprising contacting a human cell with a compound that inhibits CYP17 enzyme in the cell and antagonizes androgen receptors in the cell.
A method of inhibiting the growth of prostate cancer cells in a subject, the method comprising administering to the subject a compound that inhibits CYP17 enzyme and antagonizes an androgen receptor.
A substituted androstane compound that inhibits CYP17 enzyme and antagonizes human androgen at the androgen receptor:
Dependencies are inferred from the claim text.